Already a DIA Member? Sign in. Not a member? Join.

Sign in

Forgot User ID? or Forgot Password?

Not a Member?

Create Account and Join

Bethesda North Marriott Hotel and Conference Center

Apr 25, 2022 7:00 AM - Apr 27, 2022 12:00 PM

5701 Marinelli Road, , North Bethesda, MD 20852 , USA

DIA/FDA Oligonucleotide-Based Therapeutics Conference

DIA Your Way! Join us live in-person or live from the comfort of your home/office. This event offers two learning avenues depending on your preference!

Session 4 Track 3: CMC Perspective on Early and Late Stage Oligonucleotide Programs

Session Chair(s)

Firoz  Antia, PhD

Firoz Antia, PhD

Head of Oligonucleotide Development

Biogen, United States

In recent years, a number of oligonucleotide therapeutics have received market license authorizations in the US, Canada, Europe and other countries. There is also an increasing number of oligonucleotides entering clinical trials worldwide. This session will present recent experience with the review of CMC dossiers of early and late-stage oligonucleotide programs. Presentations from Alnylam and Ionis will be followed by a panel discussion that may include representatives from the FDA and BfArM.

Learning Objective : At the conclusion of this session, participants should be able to:
  • Gain perspective on CMC strategies for single and double stranded oligonucleotides
  • Understand current CMC expectations for market license authorizations
  • Design CMC plans for early-stage programs for longer term success


Melissa  Marschel, MS

siRNA Lifecyle: Successful Regulatory Strategies

Melissa Marschel, MS

Alnylam Pharmaceuticals, United States

Director, Regulatory Affairs

Tracey  Burr, PhD, MSc

Regulatory Interactions and Intelligence for Development and Late Phase Programs

Tracey Burr, PhD, MSc

Ionis Pharmaceuticals, United States

Director, CMC Regulatory Affairs

Lawrence  Perez, PhD


Lawrence Perez, PhD

FDA, United States

Senior Pharmaceutical Quality Assessor, CDER

René  Thürmer, PhD

René Thürmer, PhD

Federal Institute for Drugs and Medical Devices, Germany

Deputy Head of the Unit Pharmaceutical Biotechnology BfArM

Have an account?

Be informed and stay engaged.

Don't miss an opportunity - join our mailing list to stay up to date on DIA insights and events.